Targeting EGFR overexpression may be a promising novel approach in glioblastoma therapy, since small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies have already been approved in other tumor entities [6]. Here, EGFR is linked to neoplasm.